STOCK TITAN

Briacell Therapeutics Corp Stock Price, News & Analysis

BCTX Nasdaq

Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.

Briacell Therapeutics Corp (BCTX) is a clinical-stage biotechnology company pioneering novel immunotherapies for cancer treatment. This page serves as the definitive source for verified news and official updates regarding the company’s research initiatives, clinical trial progress, and strategic developments.

Investors and industry professionals will find timely updates on key programs including the Bria-IMT Phase 3 trial for metastatic breast cancer and the Bria-OTS platform’s expansion into additional oncology applications. The resource consolidates press releases, regulatory filings, and partnership announcements to provide comprehensive tracking of the company’s progress in immuno-oncology.

Content highlights include clinical trial milestones, peer-reviewed research publications, manufacturing updates, and executive commentary. All materials are sourced directly from company disclosures to ensure accuracy and compliance with financial reporting standards.

Bookmark this page for streamlined access to Briacell’s latest developments in targeted cell-based immunotherapies. Check regularly for updates on pivotal studies and emerging data from their innovative cancer treatment platforms.

Rhea-AI Summary

BriaCell Therapeutics Corp. (BCTX, BCTXW) recognizes October as Breast Cancer Awareness Month, highlighting the ongoing need for effective breast cancer treatments. The company, with $57 million cash as of July 31, 2021, continues its targeted immunotherapy program, achieving a notable 12-month overall survival benefit in trials and resolving a severe tumor in a patient. Additionally, BriaCell has initiated a securities buyback program to enhance shareholder value. The company emphasizes its commitment to treating patients beyond mere statistics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary

BriaCell Therapeutics Corp. (BCTX, BCTXW) announces significant advancements in its immunotherapy for advanced breast cancer. In a recent interview, CEO Dr. Bill Williams highlighted a partnership with ImaginAb to assess the safety and efficacy of their treatments. The board has expanded to include corporate finance expert Marc Lustig, and the company plans to utilize over $55 million in excess capital for share repurchases. Dr. Williams emphasized the need to align the company’s valuation with its clinical progress, addressing concerns regarding its current market valuation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.11%
Tags
none
-
Rhea-AI Summary

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has received approval from the TSX Venture Exchange for a normal course issuer bid (the “Buyback”). This allows the company to repurchase up to 1,341,515 common shares and 411,962 warrants over the next 12 months, starting September 28, 2021. This Buyback, managed by Independent Trading Group Inc., represents 10% of the public float as of September 21, 2021. The company assures that this initiative will not disrupt its growth plans in cancer immunotherapy and ongoing clinical trials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.92%
Tags
none
Rhea-AI Summary

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bill Williams, President and CEO, is scheduled to speak at 1:15 PM ET on September 29. The event will be held virtually, and investors can register for a free spectator pass. BriaCell focuses on immunotherapies for advanced breast cancer, aiming to provide targeted treatment approaches. For more details, visit briacell.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.44%
Tags
conferences
-
Rhea-AI Summary

BriaCell Therapeutics Corp. (BCTX, BCTXW) has authorized a repurchase program for up to 1,341,515 common shares and 411,962 warrants, representing 10% of the public float. With a cash balance of US$57 million as of July 31, 2021, the buyback is expected to enhance shareholder value. The Company is advancing its cancer immunotherapy pipeline, with key studies planned for 2022. The buyback will not interfere with BriaCell's growth initiatives in cancer treatments. Independent Trading Group will manage the repurchase program, which is subject to regulatory approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
buyback
-
Rhea-AI Summary

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced the appointment of Marc Lustig to its Board of Directors, effective September 1, 2021. Lustig, a significant shareholder with 10% ownership through L5 Capital Inc., brings extensive experience in corporate finance and pharmaceuticals. He aims to enhance the company's capital markets strategy. The Board also approved a grant of 100,000 options to Lustig at C$7.24 per share, vesting immediately, with proceeds intended for donation to the Cedars Cancer Foundation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
management
Rhea-AI Summary

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) will participate in the H.C. Wainwright 23rd Annual Global Investment Conference held virtually from September 13-15, 2021. Dr. William Williams, President & CEO, will outline the company's business during the presentation scheduled for September 13 at 7:00 A.M. (ET). Investors can access the presentation online through the provided link, with archived access for 90 days. BriaCell focuses on targeted immunotherapies for advanced breast cancer and is committed to innovative cancer management approaches.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.8%
Tags
conferences
-
Rhea-AI Summary

BriaCell Therapeutics has entered into a multi-year, non-exclusive license agreement with ImaginAb to utilize its advanced CD8 ImmunoPET imaging technology for analyzing tumor-attacking CD8 T cells in breast cancer patients. This partnership supplements BriaCell's ongoing Phase I/IIa study and aims to enhance the assessment of safety and efficacy for its immunotherapy treatments. The collaboration is expected to accelerate drug development and improve patient care, with continued clinical doses and technical support from ImaginAb.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.47%
Tags
none
-
Rhea-AI Summary

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has announced the opening of recruitment for a Phase I/IIa clinical study in collaboration with Incyte to evaluate the combination of Bria-IMT™, retifanlimab, and epacadostat for advanced breast cancer treatment. This study follows previous treatments of two patients and aims to explore novel therapeutic combinations. BriaCell expresses optimism regarding the potential effectiveness and safety of this combination, underscoring its commitment to innovative cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.57%
Tags
Rhea-AI Summary

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW), a clinical-stage biotechnology company focused on immunotherapies for advanced breast cancer, announced two upcoming virtual presentations by CEO Dr. William V. Williams. He will present at the Access to Giving Conference on July 14, 2021, and the Q3 Investor Summit on August 17, 2021. Additionally, he will speak at the SNN Network Summer Virtual Event on August 18, 2021. Each event will offer opportunities for investor meetings and live webcasts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.37%
Tags
conferences

FAQ

What is the current stock price of Briacell Therapeutics (BCTX)?

The current stock price of Briacell Therapeutics (BCTX) is $3.18 as of May 8, 2025.

What is the market cap of Briacell Therapeutics (BCTX)?

The market cap of Briacell Therapeutics (BCTX) is approximately 27.8M.
Briacell Therapeutics Corp

Nasdaq:BCTX

BCTX Rankings

BCTX Stock Data

27.78M
5.46M
12.96%
14.05%
4.96%
Biotechnology
Pharmaceutical Preparations
Link
Canada
WEST VANCOUVER